NT-3 Levels and Function in Individuals With CMT

Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy

This study will assess the serum NT-3 levels in individuals with the diagnosis of peripheral neuropathy or any type of Charcot-Marie-Tooth Neuropathy (CMT) and correlate this with function.

Study Overview

• Status: Not yet recruiting
• Conditions: Charcot-Marie-Tooth Disease; Peripheral Neuropathy; Chronic Inflammatory Demyelinating Polyneuropathy
• Intervention / Treatment: Diagnostic test: NT3 blood draw

Detailed Description

This study will assess the serum NT-3 levels in those with a peripheral neuropathy diagnosis which will help to determine the therapeutic levels of NT-3 in subjects that will receive AAV1.NT-3 gene therapy in a future study. This study also aims to define the natural history of any type of Charcot-Marie Tooth Disease (CMT), better define the rate of disease progression and skeletal muscle involvement. Another aim is to generate a registry of well-characterized CMT patients who may be candidates for future trials.

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Dawn Scott, RN; Phone Number: 614722-2715; Email: Dawn.Scott@nationwidechildrens.org

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43205
      • Nationwide Children's Hospital
      • Contact: Dawn Scott; Phone Number: (614)7222715; Email: dawn.scott@nationwidechildrens.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Male and female subjects, from 7 years of age and over with a definitive diagnosis of acquired peripheral neuropathy or genetically determined CMT neuropathy

Description

Inclusion Criteria:

• Males or females from 7 years of age or older
• Diagnosis of acquired peripheral neuropathy (PN) such as due to diabetes, chemo-induced, autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP) established by a report of electrical studies or with a known genetic CMT diagnosis. Definitive diagnosis of PN is established with a report of electrical studies, EMG/nerve conduction studies.2
• Perform assessments to the best of their ability with reliable results as deemed by the evaluator.
• Ability to attend scheduled appointments
• Ability to provide informed consent (or assent for ages 9-18)

Exclusion Criteria:

• Current pregnancy per medical history
• Has a medical condition or extenuating circumstances that, in the opinion of the investigator, might compromise the subject's wellbeing, safety, or clinical interpretability

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess change in Manual Muscle Testing (MMT)	Weakness in the major motor groups can be documented by using manual muscle testing. This exam allows the symmetry of strength, along with distribution and degree of weakness to be assessed. The Medical Research Council lists the major motor groups as: neck flexion, hip extension, knee flexion, ankle plantar flexion, and hip abduction. Depending on the clinical circumstances, the exam can be individualized. The Medical Research Council provides a scale ranging from 0-5. Inter-rater reliability will be documented by all evaluators of the trial. A rating of 5 indicates full range of motion, whereas a rating of 0 indicates no movement.	Compare baseline to Year 1 and Year 2 visits.
Assess change in 100 Meter Timed Test (100m):	Directions for study procedures will be provided in a way the subject can understand (i.e. verbal and/or written instruction, demonstration, practice, etc.). Once the subject is comfortable with study procedures, they will complete the 100m test one time. Patients will be asked to run a set course of 25 meters for 4 laps for a total distance of 100 meters. The time to complete in seconds will be recorded.	Compare baseline to Year 1 and Year 2 visits.
Assess change in Timed Functional Testing:	Timed Functional Testing can include time to ascend/descend 4 standard-sized stairs, time to rise from the floor (from NSAD), and the 10-meter run (from the NSAD).	Compare baseline to Year 1 and Year 2 visits.
Assess change in PROMIS Upper Extremity Function and Mobility Scales:	The PROMIS Upper Extremity Function and Mobility instruments are patient-reported outcomes (PRO) that utilize a patient reported and/or parent proxy scale based on the patient's age that measures an individual's perceived upper extremity function and mobility.	Compare baseline to Year 1 and Year 2 visits.
Assess change in Abilities Captured Through Interactive Video Evaluation (ACTIVE)	ACTIVE is a video game that utilizes the Microsoft Kinect camera to measure functional reaching volume while the patient is motivated to squish spiders or collect gems.	Compare baseline to Year 1 and Year 2 visits.
Assess change in CMT Pediatric Scale (CMTPedS)	The CMTPedS is a clinician-administered scale that rates patient performance on various functional activities involving the upper extremities, lower extremities, balance, and gait. The CMTPedS generates a linear score of disability ranging from 0 (not affected) to 44 (severely affected).	Compare baseline to Year 1 and Year 2 visits.
Assess change in Timed Up and Go	The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.	Compare baseline to Year 1 and Year 2 visits.
Assess change in Forced Vital Capacity	Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test.	Compare baseline to Year 1 and Year 2 visits.
Assess change in Exploratory Gait Evaluation	We may attempt to quantify gait using vibration sensors, activity monitors, or a portable walkway providing temporal spatial gait analysis.	Compare baseline to Year 1 and Year 2 visits.

Collaborators and Investigators

• Sponsor: Zarife Sahenk
• Investigators: Principal Investigator: Zarife Sahenk, MD., PhD., Nationwide Children's Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): November 13, 2027
• Primary Completion (Estimated): June 1, 2030
• Study Completion (Estimated): June 1, 2030

Study Registration Dates

• First Submitted: March 4, 2020
• First Submitted That Met QC Criteria: August 17, 2021
• First Posted (Actual): August 18, 2021

Study Record Updates

• Last Update Posted (Actual): June 24, 2025
• Last Update Submitted That Met QC Criteria: June 18, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Neuropathy; NT-3; CMT1A
• Additional Relevant MeSH Terms: Stomatognathic Diseases; Nervous System Diseases; Pathologic Processes; Neuromuscular Diseases; Chronic Disease; Disease Attributes; Genetic Diseases, Inborn; Autoimmune Diseases; Immune System Diseases; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Neurodegenerative Diseases; Congenital Abnormalities; Heredodegenerative Disorders, Nervous System; Nervous System Malformations; Polyradiculoneuropathy; Polyneuropathies; Peripheral Nervous System Diseases; Tooth Diseases; Charcot-Marie-Tooth Disease; Nerve Compression Syndromes; Hereditary Sensory and Motor Neuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
• Other Study ID Numbers: 19-0353

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No